<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Absci (ABSI) Valuation in Focus Following Partnership With Oracle Cloud and AMD for AI Drug Discovery — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Absci (ABSI) Valuation in Focus Following Partnership With Oracle Cloud and AMD for AI Drug Discovery</h2>
    <div class="badge">2025-09-15T11:27:45+00:00</div>
    <ul>
      <li>Result: Fair Value of $2.55 (ABOUT RIGHT) See our latest analysis for Absci.</li>
<li>Shares have dropped around 34% over the past year, even as the company has raised fresh funding and added new scientific expertise in its core areas.</li>
<li>Price-to-Book of 2.2x: Is it justified?</li>
<li>This partnership is landing after a year of mixed fortunes for Absci’s stock.</li>
<li>Absci is currently trading at a price-to-book (P/B) ratio of 2.2x, which is in line with the average for the US Biotechs industry but below its immediate peer group.</li>
<li>This offers a snapshot of how much investors are willing to pay for each dollar of net assets.</li>
<li>The price-to-book ratio compares the market price of a company’s shares to its book value per share.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Absci (ABSI) Valuation in Focus Following Partnership With Oracle Cloud and AMD for AI Drug Discovery\n• Result: Fair Value of $2.55 (ABOUT RIGHT) See our latest analysis for Absci.\n• Shares have dropped around 34% over the past year, even as the company has raised fresh funding and added new scientific expertise in its core areas.\n• Price-to-Book of 2.2x: Is it justified?\n• This partnership is landing after a year of mixed fortunes for Absci’s stock.\n• Absci is currently trading at a price-to-book (P/B) ratio of 2.2x, which is in line with the average for the US Biotechs industry but below its immediate peer group.\n• This offers a snapshot of how much investors are willing to pay for each dollar of net assets.\n• The price-to-book ratio compares the market price of a company’s shares to its book value per share." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/absci-absi-valuation-focus-following-112745982.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>